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was treated unevenfully with a drug-eluting balloon angioplasty. Three severely
stenosed external carotid arteries (ECAs) occluded at CAS; ECA patency rate
was 97.0% post CAS and at 30 days, and 97% at 12 months. At 12 months,
in-stent velocities were normal (PSV 0.81±0.3; EDV 0.21±0.3m/s).
Conclusions: The PARADIGM study 12-month clinical and DUS data are consis-
tent with normal healing and sustained safety and cerebral embolism prevention
efﬁcacy of the CGuard™ stent used routinely for stroke prevention in symptomatic
and increased-stroke-risk asymptomatic subjects with carotid stenosis. This indi-
cates a paradigm shift in carotid revascularization for stroke prevention.
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Background: Photoplethysmography (PPG) is a proven way to measure heart
rate (HR). This technology uses the smartphone camera as a sensor to detect
color changes in the ﬁngertip. From these color variations the heart rate can be
derived. Recently, literature and applications are demonstrating it’s use in detect-
ing arrhythmia’s such as atrial ﬁbrillation. In this work we demonstrate the use
of PPG as a method to detect regular and irregular heartbeats in a beat-to-beat
comparison with ECG. Given the widespread availability of smartphones, this re-
search provides relevant insight of an accurate digital screening tool for irregular
heartrates.
Objective: To investigate the clinical accuracy between a camera based PPG
smartphone application versus a simultaneous single-lead ECG.
Methods: For the PPG application a study camera application was used in a
non-randomized, prospective study. The camera application was compared to a
clinical validated wearable single-lead ECG patch during measurement sessions
of 60 seconds. A broad range of heartbeats were included from healthy sub-
jects and patients with atrial ﬁbrillation. Beat-to-beat intervals of simultaneously
recorded PPG and ECG were extracted and compared. The technical accuracy
was evaluated based on supervised peak-annotation.
Results: In total, 237 measurements of ECG-derived RR intervals (RRI) and
PPG-derived PP intervals (PPI) from 229 subjects were analysed. This resulted
in a 20.298 beat-to-beat intervals. An average interval of 758 ms for both RRI and
PPI was observed. A positive correlation of 0.985 for resting HR (40–100 bpm)
and 0.956 for high HR (100–170 bpm) was found between the PPI from the cam-
era application and the RRI from the wearable ECG. This result complies with the
correlation criteria of 0.90 for the validation of heart rate monitors. Results show
no signiﬁcant difference for low HR (0.76) or high HR (0.69).
Conclusion: The validation of the camera application represents a very high cor-
relation between the camera obtained PPG and the single-lead ECG. This re-
sult supports the case that the camera application could be used to monitor and
record regular and irregular HR. Therefore, smartphone applications have the
potential to become a digital tool for screening and event recording.
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Head-down tilt bed-rest (HDBR) simulates cardiac deconditioning that occur dur-
ing long duration space ﬂight. The effects of 60-days HDBR were assessed by a
novel non-invasive wearable heart kinetic (HK) cardiac monitoring method based
on calibrated combination of multi-dimensional Ballistocardiography (BCG) and
Seismocardiography (SCG). Results were compared to phase-contrast (PC) MRI-
derived stroke volume (SV). Our hypothesis was that lower stroke volume (SV)
would be associated with lower HK as a marker of cardiac contractility.
HK was measured during the ESA-RSL-BR study in a controlled breathing (CB)
protocol (7.5 breath per minute) performed before (PRE) and after 58-days
(HDT58) of BR on24 healthy males (mean age 28±6). Aortic PC-MRI was per-
formed and blood velocities were integrated over the aortic lumen area to com-
pute SV. During CB, we recorded ECG, ICG, respiration, SCG, and overall linear
(lin) and angular (rot) accelerations in 6-degrees of freedom with a miniature ac-
celerometer placed in the lumbar region. Newtonian equations of kinematics were
used to compute total heart kinetic energy (HKtot), the sum of HKrot and HKlin,
the energy transferred to the body by each cardiac contraction and a marker of
cardiac contractility.
Comparison between HDT58 and PRE showed a signiﬁcant (p<.05, paired t-test)
decrease in SV (22%) and a decrease in HKtot (27%) and HKrot (30%) but not in
HKlin.
Results from MRI and the HK monitoring
PRE HDT58 % change
RR MRI (ms) 988±114 846±113* -14
SV MRI (ml) 115±18 90±9* -22
RR (ms) 932±105 958±54 NS
LVET (ms) 191±12 169±30* -11
Fmax (N) 1.77±0.01 1.51±0.01* -15
HKlin (mJ) 4.1±0.1 3.2±0.1 NS
HKrot (mJ) 9.6±0.6 6.8±0.6* -30
HKtot (mJ) 13.7±0.9 10.0±0.7* -27
*p<0.05, paired t-test, NS: Non Signiﬁcant. MRI: parameters from the PC-MRI protocol; others:
parameters computed from the HK monitoring; PRE: baseline recordings; HDT58: recordings
after 58 days of head down tilt.
This is the ﬁrst study using HK together with PC-MRI and showing a decreased
cardiac contractility and SV after HDBR deconditioning. Decrease in HKtot was
mainly due to a decrease in rotational twist of the heart. As uni-dimensional and
linear BCG were not changed, this suggests the great advantage of total HK for
cardiac functional monitoring and it’s great potential for clinical trials.
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phone-based patient support tool on treatment duration in patients
prescribed rosuvastatin in China
X. Du1, M. Jornten-Karlsson2, Y. Xu3, J. Guo4, J. Li5, X. Mei6, L. Han7, J. Wang8,
J. Li9, Z. Shen10, A. Ryden2, M. Ahlqvist2, M. Sunden2, B.W. Karlson2, C. Ma1.
1Beijing Anzhen Hospital, Beijing, China People’s Republic of; 2AstraZeneca
Gothenburg, Mölndal, Sweden; 3Shanghai Tenth People’s Hospital, Shanghai,
China People’s Republic of; 4Beijing Luhe Hospital, Capital Medical University,
Beijing, China People’s Republic of; 5Pla 254 Hospital, Tianjin, China People’s
Republic of; 6Zhongshan Hospital, Sichuan, China People’s Republic of; 7Fuxing
Hospital, Capital Medical University, Beijing, China People’s Republic of; 8Beijing
Tongren Hospital, Capital Medical University, Beijing, China People’s Republic of;
9PLA Army General Hospital, Beijing, China People’s Republic of; 10Tong Ren
Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
People’s Republic of
Introduction: Statins reduce low-density lipoprotein cholesterol (LDL-C) and
thereby cardiovascular (CV) risk. However, in many countries, disease aware-
ness, access to treatment and patient adherence are low, and treatment duration
is often less than 3 months. Patient-focussed mobile health (mHealth) technology
using smart phone apps has the potential to provide support to large numbers
of patients at a cost that is sustainable over a long time. However, limited data
exist on the impact of these tools. This is the ﬁrst study to assess the impact
of a mHealth tool on statin treatment duration and is an important step towards
generation of evidence for patient focused mHealth.
Purpose: A randomised, two-arm, open-label exploratory study to evaluate if a
smart phone-based patient support tool prolongs statin treatment duration in pa-
tients at high CV risk.
Methods: Patients newly prescribed a statin in China were randomised (1:1) to
an Active group, which received the smart phone-based patient support tool or
to a Control group, which received only a control app. Both groups completed a
questionnaire speciﬁcally developed to evaluate adherence via their smart phone.
The primary outcome was duration of statin treatment (time from randomisation
to last patient-reported visit to a doctor for prescription renewal plus the number
of days of the last prescription). Secondary outcomes were percentage of fully
adherent patients, treatment adherence and percent change in LDL-C at Week
24.
Results: At baseline, mean age was 55 years, 63% were men, BMI was 26
kg/m2, 30% were smokers and LDL-C was 139 mg/dL, with no difference between
groups. Primary outcome data were available for 431 patients in the Active group
and 423 in the Control group. There was a trend, though not statistically signiﬁ-
cant, toward a longer mean duration of treatment in the Active group (105 days)
vs the Control group (99 days) (p=0.097). For secondary outcomes, there were
more patients who rated themselves as fully adherent in the Control group (9.9%,
n=42) than in the Active group (4.4%, n=19) (p=0.002). Treatment adherence in
terms of patient reported number of pills taken divided by the total number of pa-
tient reported days in the study varied and depended on response rate. There
was no statistically signiﬁcant difference in reduction of LDL-C between the two
groups at Week 24. None of the reported 43 adverse events were considered to
depend on the app or on rosuvastatin.
Conclusions: This innovative study shows a trend towards prolongation of dura-
tion of statin treatment with a smart phone-based patient support tool, although
not statistically signiﬁcant. mHealth will have a future to educate and motivate
patients to be more adherent, in China and other countries. Further studies to
evaluate similar support tools and technology are needed.
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